Literature DB >> 19688120

Clinical significance of vascular endothelial growth factors (VEGF)-C and -D in resected non-small cell lung cancer.

Yoon Ho Ko1, Chan-Kwon Jung, Myung-Ah Lee, Jae Ho Byun, Jin Hyoung Kang, Kyo Young Lee, Keon Hyun Jo, Young Pil Wang, Young Seon Hong.   

Abstract

PURPOSE: Lymphatic spread of tumor is an important prognostic factor for patients with non-small cell lung carcinoma (NSCLC). Vascular endothelial growth factor-C (VEGF-C) and VEGF-D play important roles in lymphangiogenesis via the VEGF receptor 3 (VEGFR-3). We sought to determine whether VEGF-C, VEGF-D and VEGFR-3 are involved in the clinical outcomes of patients with resected NSCLC.
MATERIALS AND METHODS: Using immunohistochemical staining, we investigated the protein expressions of VEGF-C, VEGF-D and VEGFR-3 in the tissue array specimens from patients who underwent resection for NSCLC. The immunoreactivity for p53 was also examined. The clinicopathological implications of these molecules were statistically analyzed.
RESULTS: Analysis of a total of 118 specimens showed that VEGF-C, VEGF-D and their co-expression were significantly associated with more advanced regional lymph node metastasis (p=0.019, p=0.044 and p=0.026, respectively, N2 versus N0 and N1). A VEGFR-3 expression had a strong correlation with peritumoral lymphatic invasion (p=0.047). On the multivariate analysis for survival and recurrence, pathologic N2 lymph node metastasis was the only independent prognostic factor, but none of the investigated molecules showed any statistical correlation with recurrence and survival.
CONCLUSIONS: The present study revealed that high expressions of VEGF-C and VEGF-D were strongly associated with more advanced regional lymph node metastasis in patients with resected NSCLC.

Entities:  

Keywords:  Carcinoma; Lymphangiogenesis; Neoplasm metastasis; Non-small-cell lung; Vascular endothelial growth factor

Year:  2008        PMID: 19688120      PMCID: PMC2697470          DOI: 10.4143/crt.2008.40.3.133

Source DB:  PubMed          Journal:  Cancer Res Treat        ISSN: 1598-2998            Impact factor:   4.679


  24 in total

1.  Conventional clinicopathologic prognostic factors in surgically resected nonsmall cell lung carcinoma. A comparison of prognostic factors for each pathologic TNM stage based on multivariate analyses.

Authors:  K Suzuki; K Nagai; J Yoshida; M Nishimura; K Takahashi; T Yokose; Y Nishiwaki
Journal:  Cancer       Date:  1999-11-15       Impact factor: 6.860

Review 2.  Regulation of angiogenesis via vascular endothelial growth factor receptors.

Authors:  T Veikkola; M Karkkainen; L Claesson-Welsh; K Alitalo
Journal:  Cancer Res       Date:  2000-01-15       Impact factor: 12.701

3.  Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma.

Authors:  Stefan Jüttner; Christoph Wissmann; Thomas Jöns; Michael Vieth; Johannes Hertel; Stephan Gretschel; Peter M Schlag; Wolfgang Kemmner; Michael Höcker
Journal:  J Clin Oncol       Date:  2005-12-12       Impact factor: 44.544

4.  Vascular endothelial growth factor-D expression is an independent prognostic marker for survival in colorectal carcinoma.

Authors:  Jeff D White; Peter W Hewett; Dennis Kosuge; Thomas McCulloch; Berndt C Enholm; James Carmichael; J Clifford Murray
Journal:  Cancer Res       Date:  2002-03-15       Impact factor: 12.701

5.  Vascular endothelial growth factor and other biological predictors related to the postoperative survival rate on non-small cell lung cancer.

Authors:  M Liao; H Wang; Z Lin; J Feng; D Zhu
Journal:  Lung Cancer       Date:  2001 Aug-Sep       Impact factor: 5.705

6.  Combined analysis of cyclooxygenase-2 expression with p53 and Ki-67 in nonsmall cell lung cancer.

Authors:  Hiroyoshi Tsubochi; Nobuyuki Sato; Misae Hiyama; Mitsuomi Kaimori; Shunsuke Endo; Yasunori Sohara; Tadashi Imai
Journal:  Ann Thorac Surg       Date:  2006-10       Impact factor: 4.330

7.  Clinicopathological and prognostic significance of vascular endothelial growth factors (VEGF)-C and -D and VEGF receptor 3 in invasive breast carcinoma.

Authors:  E Mylona; P Alexandrou; A Mpakali; I Giannopoulou; G Liapis; S Markaki; A Keramopoulos; L Nakopoulou
Journal:  Eur J Surg Oncol       Date:  2006-11-28       Impact factor: 4.424

8.  Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma.

Authors:  Mitsuyuki Arinaga; Tsuyoshi Noguchi; Shinsuke Takeno; Masao Chujo; Takashi Miura; Yuzo Uchida
Journal:  Cancer       Date:  2003-01-15       Impact factor: 6.860

9.  Enhancement of pleural dissemination and lymph node metastasis of intrathoracic lung cancer cells by vascular endothelial growth factors (VEGFs).

Authors:  Haruhiko Ishii; Takuya Yazawa; Hanako Sato; Takehisa Suzuki; Masaichi Ikeda; Yasufumi Hayashi; Yoshinori Takanashi; Hitoshi Kitamura
Journal:  Lung Cancer       Date:  2004-09       Impact factor: 5.705

10.  Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma.

Authors:  Y Yokoyama; D S Charnock-Jones; D Licence; A Yanaihara; J M Hastings; C M Holland; M Emoto; M Umemoto; T Sakamoto; S Sato; H Mizunuma; S K Smith
Journal:  Br J Cancer       Date:  2003-01-27       Impact factor: 7.640

View more
  7 in total

1.  Supplementation with alpha-tocopherol or beta-carotene reduces serum concentrations of vascular endothelial growth factor-D, but Not -A or -C, in male smokers.

Authors:  Alison M Mondul; Helen C Rager; William Kopp; Jarmo Virtamo; Demetrius Albanes
Journal:  J Nutr       Date:  2011-09-28       Impact factor: 4.798

2.  Multiplexed analysis of angiogenesis and lymphangiogenesis factors predicts outcome for non-small cell lung cancer patients.

Authors:  Valsamo K Anagnostou; Dina G Tiniakos; Marianthi Fotinou; Apostolos Achimastos; Konstantinos N Syrigos
Journal:  Virchows Arch       Date:  2010-12-14       Impact factor: 4.064

3.  Lymphangiogenesis in gastric cancer regulated through Akt/mTOR-VEGF-C/VEGF-D axis.

Authors:  Hongxia Chen; Runnian Guan; Yupeng Lei; Jianyong Chen; Qi Ge; Xiaoshen Zhang; Ruoxu Dou; Hongyuan Chen; Hao Liu; Xiaolong Qi; Xiaodong Zhou; Changyan Chen
Journal:  BMC Cancer       Date:  2015-03-07       Impact factor: 4.430

4.  High density of peritumoral lymphatic vessels measured by D2-40/podoplanin and LYVE-1 expression in gastric cancer patients: an excellent prognostic indicator or a false friend?

Authors:  Julia Rudno-Rudzinska; Wojciech Kielan; Zygmunt Grzebieniak; Piotr Dziegiel; Piotr Donizy; Grzegorz Mazur; Monika Knakiewicz; Ewelina Frejlich; Agnieszka Halon
Journal:  Gastric Cancer       Date:  2012-12-14       Impact factor: 7.370

5.  Prediction of VEGF and EGFR Expression in Peripheral Lung Cancer Based on the Radiomics Model of Spectral CT Enhanced Images.

Authors:  Linhua Wu; Jian Li; Xiaowei Ruan; Jialiang Ren; Xuejun Ping; Bing Chen
Journal:  Int J Gen Med       Date:  2022-08-22

Review 6.  Lymphangiogenic Markers and Their Impact on Nodal Metastasis and Survival in Non-Small Cell Lung Cancer--A Structured Review with Meta-Analysis.

Authors:  Thomas K Kilvaer; Erna-Elise Paulsen; Sigurd M Hald; Tom Wilsgaard; Roy M Bremnes; Lill-Tove Busund; Tom Donnem
Journal:  PLoS One       Date:  2015-08-25       Impact factor: 3.240

Review 7.  Pazopanib and anti-VEGF therapy.

Authors:  Harry A Drabkin
Journal:  Open Access J Urol       Date:  2010-03-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.